Key Takeaways CorMedix's shares fell 31% in a month after management issued conservative 2026 revenue guidance.CRMD guided 2026 revenues of $300-$320M, with DefenCath sales expected to be $150-$170 million.CRMD added diversification via the Melinta deal, with seven drugs and likely near-term growth from Rezzayo.Shares of CorMedix (CRMD) have declined sharply over the past month, reflecting investor concerns following its bearish 2026 financial outlook. The guidance points to a more conservative growth traje ...